Mutations in the LMNA gene are associated with a wide spectrum of disease phenotypes, ranging from neuromuscular, cardiac and metabolic disorders to premature aging syndromes. Skeletal muscle involvement may present with different phenotypes: limb-girdle muscular dystrophy type 1B or LMNA-related dystrophy; autosomal dominant Emery-Dreifuss muscular dystrophy; and a congenital form of muscular dystrophy, frequently associated with early onset of arrhythmias. Heart involvement may occur as part of the muscle involvement or independently, regardless of the presence of the myopathy. Notably conduction defects and dilated cardiomyopathy may exist without a muscle disease. This paper will focus on cardiac diseases presenting as the first manifestation of skeletal muscle hereditary disorders such as laminopathies, inspired by two large families with cardiovascular problems long followed by conventional cardiologists who did not suspect a genetic muscle disorder underlying these events. Furthermore it underlines the need for a multidisciplinary approach in these disorders and how the figure of the cardio-myo-geneticist may play a key role in facilitating the diagnostic process, and addressing the adoption of appropriate prevention measures.

Key words: laminopathies, risk stratification, genetic counselling

Introduction

Muscular dystrophies (MD) are a heterogeneous group of inherited disorders that share similar clinical features and dystrophic changes on muscle biopsy, associated with progressive weakness (1-4). Weakness may be noted at birth or develop in late adult life. Some patients manifest with myalgias, rhabdomyolysis, or only raised serum creatine kinase (CK) levels without any symptoms or signs of weakness.

Early- or childhood-onset muscular dystrophies may be associated with profound loss of muscle function affecting ambulation, posture, and cardiac and respiratory function. Late-onset muscular dystrophies may be mild and associated with slight weakness and inability to increase muscle mass (3, 4). A better understanding of the molecular bases of MD has led to more accurate definitions of the clinical features and a new classification.

Knowledge of disease-specific complications, implementation of anticipatory care, and medical advances have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected people (5-9).

Muscular dystrophies can present an autosomal dominant, autosomal recessive, or a X-linked pattern of inheritance and can result from mutations affecting structural proteins localizable to the sarcolemma, nuclear or basement membrane, sarcomere, or non-structural enzymatic proteins (1, 2).

In recent years, cardiac involvement has been observed in a growing number of genetic muscle diseases, and considerable progress has been made in understanding the relationships between disease skeletal muscle and cardiac muscle disease (5-9). Significant advances in respiratory care have only recently unmasked cardiomyopathy as a significant cause of death in MD (10-15).

In several forms of MD, cardiac disease may even be the predominant manifestation of the underlying genetic myopathy and precede of many years the onset of skeletal...
muscle involvement. Unfortunately “conventional” cardiologists may be unfamiliar with these diseases due to their low incidence, while an early detection of MD-associated cardiomyopathy is of considerable importance, as a prompt institution of cardio-protective medical or supportive therapies may slow adverse cardiac remodeling and attenuate heart failure symptoms or avoid the occurrence of sudden cardiac death in these patients (16-18).

Standard and dynamic electrocardiography (ECG and ECG Holter) and echocardiography are typically advocated for screening, although very recently, cardiovascular magnetic resonance (CMR) has shown promise in revealing early cardiac involvement when standard cardiac evaluation is still unremarkable (15-17).

This paper will focus on cardiac diseases presenting as the first manifestation of skeletal muscle hereditary disorders such as laminopathies, inspired by two large families with cardiovascular problems long followed by conventional cardiologists who did not suspect a genetic muscle disorder underlying these events.

Patients

Family 1

In the first family, the proband was a 15 years old young boy who underwent heart surgery for aortic coarctation. He had a bicuspid aortic valve, present in his cousin too. Family history revealed that the maternal grandfather had been implanted with a pacemaker (PMK) at the age of 50 years upgraded to an implantable cardioverter-defibrillator ICD for severe systolic dysfunction 5 years later, and received heart transplantation (HT) for severe dilated cardiomyopathy, at 60 years. Unfortunately he did not survive post-transplant complications. The great grandmother underwent PMK implantation too (Fig. 1).

During a genetic counselling, requested to investigate a possible genetic background explaining the familial occurrence of aortic valve defects, a cardiomyopathy associated genes NGS panel was performed, that unexpectedly revealed the c.673C > T (p.Arg225Ter) mutation in LMNA gene, maternally inherited. The mother, asymptomatic carrier of the mutation, underwent cardiological checks which showed a dilated cardiomyopathy and the presence of a first degree atrio-ventricular block, requiring ICD implantation.

Family 2

In the second family, the index case – a female aged 58y – was referred to our service in May 2016 for an apparently asymptomatic hyperCKemia (2x). An accurate reconstruction of the family history revealed a high frequency of pacemaker (4 sibling) and sudden cardiac death associated to presence of conduction anomalies in her father (Fig. 2). A diagnosis of dilated cardiomyopathy following an acute myocarditis had been previously made because an episode of pneumonia. As during the hospitalization a new cardiological assessment revealed a second degree atrio-ventricular block, the patient was promptly referred to our arrhythmologic Unit to be implanted with an ICD. Based on family history of multiple cardiac devices implantation, a diagnosis of laminopathy was first suspected and subsequently confirmed by LMNA gene analysis that showed the mutation c.207delG (p.Val70Ser fs X26) in both the proband and her two sisters. In one of them, previously implanted with a PMK for conduction anomalies, an upgrading to an ICD-R was necessary due to the presence of a dilated cardiomyopathy with progressive reduction of the ejection fraction (< 35%). The cardiological assessment of the third sister showed a first degree atrio-ventricular block and a not sustained ventricular tachycardia on the ECG Holter, requiring an ICD implantation.

Discussion

Laminopathies or LMNA-related disorders are rare genetic diseases caused by mutations in LMNA gene, which encodes, via alternative splicing, for lamins A and C, structural proteins of the nuclear envelope. These proteins play a role in several cellular processes, and mutations in the LMNA gene are associated with a wide range of disease phenotypes, ranging from neuromuscular, cardiac and metabolic disorders to premature aging syn-
Cardiac diseases as a predictor warning of hereditary muscle diseases. The case of laminopathies

dromes (19-27). Skeletal muscle involvement may present as autosomal dominant/recessive Emery-Dreifuss muscular dystrophy, LGMD type 1B or LMNA-related congenital muscular dystrophy (LMNA-CMD).

Lamin A/C gene mutations can be associated with cardiac diseases, usually referred to as ‘cardio-laminopathies’ mainly characterized by arrhythmic disorders and less frequently by left ventricular or biventricular dysfunction up to an overt heart failure (28-32). Heart involvement shows a high penetrance, and almost all patients after the seventh decade of life show cardiac disease, regardless of the presence of the myopathy. On the contrary, conduction tissue defects and dilated cardiomyopathy may exist without muscle disease, although subtle muscle involvement may be present and underestimated (29, 31).

Phenotypic penetrance is age-related but the expression of the disease is extremely heterogeneous, so that muscular and arrhythmic disease can be present in combination in the same patient, or in an independent way or remain hidden for a long time. Moreover, both the severity of the disease and its progression may have a marked inter- and intra-familial variability. Sudden cardiac death may be the only manifestation of the disease (31).

Conclusions

From a cardiological point of view, characterization of patients affected by “cardio-laminopathy” is of crucial importance, since clinical and prognostic implications, as well as specific management strategies, can be different, particularly with regard to prevention of sudden cardiac death (33-39).

A specific diagnosis – based on an accurate familial/personal anamnesis and/or family pedigree and genetic testing – is currently needed in patients affected by the various manifestations of these diseases. Furthermore, an appropriate risk stratification with referral to expert centres involving a multidisciplinary team for a proper decision-making is recommended.

In this context the medical geneticist can play a key role in reconstructing the family history and addressing the access to NGS sequencing or the appropriate single-gene analysis, ultimately facilitating the diagnostic process.

In addition we hope for a closer cooperation among cardiologists, experts in cardio-myopathies and geneticists to create a new professional figure, the cardio-myogeneticist, with specific expertise and knowledge in all the diagnostic aspects of heart muscle disorders, to improve the management of patients.

Conflict of interest

The Authors declare to have no conflict of interest.

References

1. Emery AE. The muscular dystrophies. Lancet 2002;359:687-95
2. McNally EM, Pytel P. Muscle diseases: the muscular dystrophies. Annu Rev Pathol 2007;2:87-109.
3. Sewry CA. Muscular dystrophies: an update on pathology and diagnosis. Acta Neuropathol 2010;120:343-58.
4. Amato AA, Griggs RC. Overview of the muscular dystrophies. Handb Clin Neurol 2011;101:1-9.
5. Bouhouch R, Elhouari T, Ouerraj L, et al. Management of cardiac involvement in neuromuscular diseases: review. Open Cardiovasc Med J 2008;2:93-6.
6. Arbusi E, Di Toro A, Giuliani L, et al. Cardiac phenotypes in hereditary muscle disorders: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:2485-306
7. Silvestri NJ, Ismail H, Zimetbaum P, et al. Cardiac involvement in the muscular dystrophies. Muscle Nerve 2018;57:707-15
8. Sommerville RB, Vincenti MG, Winborn K, et al. Diagnosis and management of adult hereditary cardiac-neuromuscular disorders: a model for the multidisciplinary care of complex genetic disorders. Trends Cardiovasc Med 2017;27:51-8.
9. Finsterer J, Stöllberger C, Wahbi K. Cardiomyopathy in neurological disorders. Cardiовasc Pathol 2013;22:389-400.
10. Naddaf E, Milone M. Hereditary myopathies with early respiratory insufficiency in adults. Muscle Nerve 2017;56:881-6.
11. Kinnear W, Colt J, Watson L, et al. Long-term non-invasive ventilation in muscular dystrophy. Chron Respir Dis 2017;14:33-6.
12. Kawai M. Neuromuscular disease and sleep disturbance. Rinsho Shinkeigaku 2014;54:984-6.
13. Simonds AK. Respiratory support for the severely handicapped child with neuromuscular disease: ethics and practicality. Semin Respir Crit Care Med 2007;28:342-54.
14. Kalra M, Amin RS. Pulmonary management of the patient with muscular dystrophy. Pediatr Ann 2012;41:43-5.
15. de Visser M, Van den Ouweland A, Van der Bosch E, et al. Cardiac involvement in muscular dystrophy. J Neurol Sci 1996;141:95-6.
16. Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 2007;49:1874-9.
17. Verhaert D, Richards K, Rafael-Fortney JA, et al. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 2011;4:67-76.
18. Otto RK, Fergusson MR, Friedman SD. Cardiac MRI in muscular dystrophy: an overview and future directions. Phys Med Rehabil Clin N Am 2012;23:123-32, xi-xii.
19. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-8.
20. Brull A, Morales Rodriguez B, Bonne G, et al. The pathogenesis and therapies of striated muscle laminopathies. Front Physiol 2018;9:1533
21. Lattanzi G, Benedetti S, Bertini E, et al. Laminopathies: many diseases, one gene. Report of the first Italian Meeting Course on Laminopathies. Acta Myol 2011;30:138-43.
22. Politano L, Carboni N, Madej-Pilarczyk A, et al. Advances in basic and clinical research in laminopathies. Acta Myol 2013;32:18-22.
23. Carboni N, Politano L, Floris M, et al. Overlapping syndromes in laminopathies: a meta-analysis of the reported literature. Acta Myol 2013;32:7-17.
24. Maggi L, D’Amico A, Pini A, et al. LMNA-associated myopathies: the Italian experience in a large cohort of patients. Neurology 2014;83:1634-44.
25. Petillo R, D’Ambrosio P, Torella A, et al. Novel mutations in LMNA A/C gene and associated phenotypes. Acta Myol 2015;34:116-9.
26. Maggi L, Carboni N, Bernasconi P. Skeletal muscle laminopathies: a review of clinical and molecular features. Cells 2016;5(3).
27. Kang SM, Yoon MH, Park BJ. Laminopathies; mutations on single gene and various human genetic diseases. BMB Rep 2018;51:327-37.
28. Vytopil M, Benedetti S, Ricci E, et al. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomyopathic phenotypes. J Med Genet 2003;40:e132.
29. Captur G, Arbusi E, Bonne G, et al. Lamin and the heart. Heart 2018;104:468-79.
30. Cattin ME, Muchir A, Bonne G. ‘State-of-the-heart’ of cardiac laminopathies. Curr Opin Cardiol 2013;28:297-304.
31. Captur G, Arbusi E, Syrris P, et al. Lamin mutation location predicts cardiac phenotype severity: combined analysis of the published literature. Open Heart 2018;5:e000915.
32. Narula N, Favalli V, Tarantino P, et al. Quantitative expression of the mutated lamin A/C gene in patients with cardiolaminopathy. J Am Coll Cardiol 2012;60:1916-20.
33. Peretto G, Sala S, Benedetti S, et al. Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease. Nucleus 2018;9:380-91.
34. Fayssoil A. Risk stratification in laminopathies and Emery Dreifuss muscular dystrophy. Neuro Int 2018;10:7468.
35. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52:1250-60.
36. Russo V, Nigo G. ICD role in preventing sudden cardiac death in Emery-Dreifuss muscular dystrophy with preserved myocardial function: 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Europace 2015;17:337.
37. Russo V, Rago A, Nigo G. Sudden cardiac death in neuromuscular disorders: time to establish shared protocols for cardiac pacing. Int J Cardiol 2016;207:284-5.
38. Wang X, Zabell A, Koh W, et al. Lamin A/C cardiomyopathies: current understanding and novel treatment strategies. Curr Treat Options Cardiovasc Med 2017;19:21.
39. Boriani G, Biagini E, Ziaichi M, et al. Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes. Nucleus 2018;9:442-59.

How to cite this article: D’Ambrosio P, Petillo R, Torella A, et al. Cardiac diseases as a predictor warning of hereditary muscle diseases. The case of laminopathies. Acta Myol 2019;38:33-36.